Navigation Links
Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception'
Date:6/17/2010

WASHINGTON, June 17 /PRNewswire-USNewswire/ -- The chairman of the U.S. bishops' Committee on Pro-Life Activities voiced "grave concern" to the U.S. Food and Drug Administration (FDA) over its move toward approving a new drug that may induce early abortions as an "emergency contraceptive." In a June 17 letter to Dr. Margaret Hamburg, Commissioner of the FDA, Cardinal Daniel DiNardo of Galveston-Houston criticized the FDA's move to hold an advisory committee meeting on the drug Ulipristal "without broad public input or a full record on the drug's safety for women or their unborn children."

The Cardinal raised concerns that Ulipristal is more similar in effect to the drug RU-486, which can cause abortions several weeks into pregnancy, than it is to other emergency contraceptives, which are believed to have no post-implantation effects.

"Millions of American women, even those willing to use a contraceptive to prevent fertilization in various circumstances, would personally never choose to have an abortion," said Cardinal DiNardo. "They would be ill served by a misleading campaign to present Ulipristal simply as a 'contraceptive.' In fact, FDA approval for that purpose would likely make the drug available for 'off-label' use simply as an abortion drug – including its use by unscrupulous men with the intent of causing an early abortion without a woman's knowledge or consent. Such abuses have already occurred in the case of RU-486, despite its warning labels and limited distribution."

Cardinal DiNardo went on to cite the support of this and previous Administrations for federal laws ensuring no one is involved in an abortion without his or
'/>"/>

SOURCE U.S. Conference of Catholic Bishops Secretariat for Pro-Life Activities
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
3. Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect
4. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
5. Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute
6. Dr. Derek Winstanly of Quintiles to Serve as 2009 ACRO Chair; Mr. William Sharbaugh of PPD to Be Chair-Elect
7. Spherix Elects New Independent Director, and Elects Chairman of the Board
8. CeQur SA Appoints Eric Milledge Chairman of the Board of Directors
9. National Pharmaceutical Council Board of Directors Elects Pfizers Marie-Caroline Sainpy as Chairman
10. Stryker Announces Change in Chairman of the Board of Directors
11. Bracken to Become Chairman of HCAs Board of Directors Effective Dec. 15
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... DIEGO , Sept. 16, 2014 Imprimis ... pharmaceutical company dedicated to delivering high quality and novel ... announced that Chief Executive Officer Mark Baum ... Annual Craig-Hallum Alpha Select Conference in New York City.  ... its Go Dropless™ campaign in ophthalmology. The presentation ...
(Date:9/16/2014)... -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing ... today that it has entered into an agreement with ... of animal studies for levorphanol, the active ingredient of ... levorphanol.  Gavril Pasternak, MD, PhD, of MSKCC is the ... Pasternak said, "Levorphanol is a unique opioid analgesic that ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... COLLEGEVILLE, Pa., May 30 Wyeth,Pharmaceuticals, a ... today announced the,initiation of the INTORACT (INvestigation ... worldwide randomized, open-label, phase 3b,study comparing TORISEL(R) ... for first-line treatment of patients,with advanced renal ...
... evaluation of safety and tolerability, as ... 2 trials -, ROCKVILLE, Md., May 30 ... that it has initiated dosing in a Phase,1 clinical ... lead IAP,inhibitor, HGS1029, as monotherapy in patients with advanced ...
Cached Medicine Technology:Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 2Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 3Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 4Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 5Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 6Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 2Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 3Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 4
(Date:9/16/2014)... Francisco, September 15, 2014A prospective study that compared ... patients with bone metastases demonstrates that single fraction ... multiple fraction radiation therapy (MFRT) when pain, function ... research presented today at the American Society for ... study indicates that improvements in patients, pain, function ...
(Date:9/16/2014)... Texas (PRWEB) September 16, 2014 Beginning October ... adding a new service offering for its clients who book ... to the volume of business they buy. Most recurring ... during the work week, but others include clients whose ... pet sitter on a daily basis. The ...
(Date:9/16/2014)... Founded by former Miami Beach mayoral candidate Steve ... fighting to legalize medical marijuana in Florida. Advocating for ... recently commissioned a shot-for-shot parody video of the song ... “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called “You’re the Law ... faithfully recreates the carnival scene made famous by John ...
(Date:9/16/2014)... Florida Hospital announced today it is teaming ... partnership and become the Presenting Sponsor of the 2014-15 ... health and wellness partner. As the Presenting Sponsor for ... logo and name inclusion on all Lightning advertising campaigns ... has been a sponsorship partner of the Lightning since ...
(Date:9/16/2014)... reduce the risk of heart disease or stroke, even ... part of the diet. , A study of ... from Monash University,s Department of Epidemiology and Preventive Medicine ... consumption of dairy foods had played in the country,s ... dominantly Chinese food culture, unaccustomed to dairy foods, consuming ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2
... Large study suggests the procedure impairs healthy immune response ... by Caesarean section are at increased risk of asthma, ... the respiratory health of nearly 3,000 infants. , By ... percent) of the children had been diagnosed with asthma ...
... the year. , ... (PRWEB) November 2, 2009 -- For the ... treatment Frontline , to UK mainland addresses, excluding the highlands and islands, ... the Hyperdrug.co.uk web site. , , ,Hyperdrug director Ben Watson says "Hyperdrug ...
... INDIANAPOLIS, Dec. 3 Vertellus Specialties Inc., a leading specialty ... January 1, 2009 for 2-vinylpyridine monomer sales to all non-contract ... investment in production capacity and to provide better supply chain ... About Vertellus Specialties Inc. ...
... positive airway pressure (CPAP) treatment seems to improve cognitive ... from obstructive sleep apnea, according to the results of ... California, San Diego. The study led by Sonia ... Diego School of Medicine and one of the nation,s ...
... the availability of Trade Alerts on stocks making news today. , ... notes for free by visiting: http://www.BeaconEquity.com/m , , ... ), Williams-Sonoma Inc. (NYSE: WSM ), Medicis Pharmaceutical Corp. (NYSE: ... Group Co. (Nasdaq: MHGC ) and DSP Group Inc. (Nasdaq: ...
... the body to selectively suppress the immune response may ... to scientists. , "If you like, what we are ... more like a fetus," said Dr. Andrew L. Mellor, ... and Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics. ...
Cached Medicine News:Health News:C-Section Might Boost Baby's Asthma Risk 2Health News:Beating the Credit Crunch with Hyperdrug.co.uk 2Health News:Treating sleep apnea in Alzheimer's patients helps cognition 2Health News:Treating sleep apnea in Alzheimer's patients helps cognition 3Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: SPC, WSM, MRX, WXS, MHGC, DSPG 2Health News:New approaches to protecting transplanted organs make first steps toward patients 2Health News:New approaches to protecting transplanted organs make first steps toward patients 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: